An investigational therapeutic vaccine getting developed to take care of herpes simplex virus-2.

Antigenics announces excellent results of AG-707 genital herpes vaccine Antigenics announced positive results with AG-707, an investigational therapeutic vaccine getting developed to take care of herpes simplex virus-2 , the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells. Latest data suggest both these hands of immunity are necessary for successful treatment of genital herpes http://tadalafil-espana.com .D., research professor and investigator of Medication, Laboratory Global and Medication Health Medication, University of Washington. We are very encouraged by these outcomes. Recent data suggest both of these hands of immunity are needed for effective treatment of genital herpes.

oral use

Anal malignancy had elevated by about 3.4 per cent annually in men and 1.9 per cent in women since 1982, based on the scholarly research published in the journal Vaccine. Related StoriesSausages With Antioxidants From Berries TO AVOID CancerStudy shows uncommon HER2 missense mutations usually do not spread breasts cancer on the ownMD Anderson study reveals why chemotherapy medicines not effective for many pancreatic cancers patientsGardasil is accepted in Australia for use in boys and men aged nine to 26. Without subsidy, it costs $450 a treatment, and most parents are unaware of the protection it provides boys.

Other entries from category "treatments":

Random entries